Advancements in protein sequencing technologies make it possible to work off of the exact amino acid sequence of any antibody species, allowing easy modification. This knowledge both enables and simplifies grafting any host regions of interest onto a desired backbone.
Next generation protein sequencing (NGPS) continues to facilitate recombinant expression to ease manipulation and engineering. More importantly, when modifications, mispairings, or mutations occur through time, proteomics can also help confirm the protein sequence in every step throughout the therapeutic pipeline.
Research teams are using NGPS for therapeutic and diagnotic projects focused on humanization and/or chimerization of antibodies, development of nanobodies, scvFs, and/or engineering of bi/tri/multi-specific antibodies.